Literature DB >> 29236957

Pharmacogenomics: time to rethink its role in precision medicine.

J A Willis1, E Vilar2.   

Abstract

Mesh:

Year:  2018        PMID: 29236957      PMCID: PMC6248583          DOI: 10.1093/annonc/mdx780

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  23 in total

Review 1.  Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

Authors:  Peter J O'Dwyer; Robert B Catalano
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

2.  Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Authors:  A Abad; E Martínez-Balibrea; J M Viéitez; V Alonso-Orduña; P García Alfonso; J L Manzano; B Massutí; M Benavides; A Carrato; M Zanui; J Gallego; C Grávalos; V Conde; M Provencio; M Valladares-Ayerbes; R Salazar; J Sastre; C Montagut; F Rivera; E Aranda
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 32.976

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

Authors:  R de las Peñas; M Sanchez-Ronco; V Alberola; M Taron; C Camps; R Garcia-Carbonero; B Massuti; C Queralt; M Botia; R Garcia-Gomez; D Isla; M Cobo; M Santarpia; F Cecere; P Mendez; J J Sanchez; R Rosell
Journal:  Ann Oncol       Date:  2006-01-11       Impact factor: 32.976

Review 5.  Designing transformative clinical trials in the cancer genome era.

Authors:  Stefan Sleijfer; Jan Bogaerts; Lillian L Siu
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

6.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Authors:  Federico Innocenti; Samir D Undevia; Lalitha Iyer; Pei Xian Chen; Soma Das; Masha Kocherginsky; Theodore Karrison; Linda Janisch; Jacqueline Ramírez; Charles M Rudin; Everett E Vokes; Mark J Ratain
Journal:  J Clin Oncol       Date:  2004-03-08       Impact factor: 44.544

Review 7.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Authors:  Didier Meulendijks; Linda M Henricks; Gabe S Sonke; Maarten J Deenen; Tanja K Froehlich; Ursula Amstutz; Carlo R Largiadèr; Barbara A Jennings; Anthony M Marinaki; Jeremy D Sanderson; Zdenek Kleibl; Petra Kleiblova; Matthias Schwab; Ulrich M Zanger; Claire Palles; Ian Tomlinson; Eva Gross; André B P van Kuilenburg; Cornelis J A Punt; Miriam Koopman; Jos H Beijnen; Annemieke Cats; Jan H M Schellens
Journal:  Lancet Oncol       Date:  2015-10-23       Impact factor: 41.316

8.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

9.  Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Authors:  Giuseppe Toffoli; Erika Cecchin; Giampiero Gasparini; Mario D'Andrea; Giuseppe Azzarello; Umberto Basso; Enrico Mini; Sergio Pessa; Elena De Mattia; Giovanni Lo Re; Angela Buonadonna; Stefania Nobili; Paolo De Paoli; Federico Innocenti
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

10.  Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Authors:  Li-Ming Tan; Cheng-Feng Qiu; Tao Zhu; Yuan-Xiang Jin; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.